NASDAQ:SMMT Summit Therapeutics (SMMT) Stock Price, News & Analysis $21.43 +0.56 (+2.68%) Closing price 10/3/2025 04:00 PM EasternExtended Trading$21.35 -0.08 (-0.37%) As of 10/3/2025 07:41 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsBuy This Stock About Summit Therapeutics Stock (NASDAQ:SMMT) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Summit Therapeutics alerts:Sign Up Key Stats Today's Range$20.48▼$21.4950-Day Range$17.60▼$29.3252-Week Range$15.55▼$36.91Volume2.24 million shsAverage Volume5.64 million shsMarket Capitalization$15.92 billionP/E RatioN/ADividend YieldN/APrice Target$31.29Consensus RatingHold Company Overview Summit Therapeutics plc is a clinical‐stage biotechnology company dedicated to the discovery and development of precision medicines for serious and life‐threatening diseases. The company applies a targeted approach to drug design, focusing on novel mechanisms of action that differentiate its candidates from existing therapies. Summit’s lead asset, ridinilazole (formerly SMT19969), is being developed to treat Clostridioides difficile infections and has received both Fast Track and Qualified Infectious Disease Product designations from the U.S. Food and Drug Administration. Alongside its infectious disease program, Summit has explored small‐molecule therapies for rare genetic disorders, leveraging its drug discovery capabilities to identify compounds that modulate disease‐relevant pathways. Founded in 2003 and headquartered in Oxford, England, Summit maintains operations in North America to support clinical development and regulatory activities across the United States and Europe. The company’s management team brings extensive experience in biopharmaceutical research, clinical operations, and commercialization strategy, with a commitment to advancing its pipeline toward regulatory approval and broad patient access.AI Generated. May Contain Errors. Read More Summit Therapeutics Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks61st Percentile Overall ScoreSMMT MarketRank™: Summit Therapeutics scored higher than 61% of companies evaluated by MarketBeat, and ranked 415th out of 941 stocks in the medical sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion4.2 / 5Analyst RatingHold Consensus RatingSummit Therapeutics has received a consensus rating of Hold. The company's average rating score is 2.44, and is based on 11 buy ratings, 1 hold rating, and 5 sell ratings.Upside PotentialSummit Therapeutics has a consensus price target of $31.29, representing about 46.0% upside from its current price of $21.43.Amount of Analyst CoverageSummit Therapeutics has been the subject of 10 research reports in the past 90 days, demonstrating strong analyst interest in this stock.Read more about Summit Therapeutics' stock forecast and price target. Earnings and Valuation0.0 / 5Proj. Earnings GrowthDecreasing Earnings GrowthEarnings for Summit Therapeutics are expected to decrease in the coming year, from ($0.30) to ($0.36) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Summit Therapeutics is -21.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Summit Therapeutics is -21.22, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioSummit Therapeutics has a P/B Ratio of 40.43. P/B Ratios above 3 indicate that a company could be overvalued with respect to its assets and liabilities.Read more about Summit Therapeutics' valuation and earnings. Short Interest2.0 / 5Short Interest LevelBearish Percentage of Shares Shorted4.34% of the outstanding shares of Summit Therapeutics have been sold short.Short Interest Ratio / Days to CoverSummit Therapeutics has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Summit Therapeutics has recently increased by 8.38%, indicating that investor sentiment is decreasing significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldSummit Therapeutics does not currently pay a dividend.Dividend GrowthSummit Therapeutics does not have a long track record of dividend growth. Sustainability and ESGN/AEnvironmental ScoreN/A Percentage of Shares Shorted4.34% of the outstanding shares of Summit Therapeutics have been sold short.Short Interest Ratio / Days to CoverSummit Therapeutics has a short interest ratio ("days to cover") of 7.9.Change versus previous monthShort interest in Summit Therapeutics has recently increased by 8.38%, indicating that investor sentiment is decreasing significantly. News and Social Media2.4 / 5News Sentiment0.37 News SentimentSummit Therapeutics has a news sentiment score of 0.37. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a lower news sentiment than the 0.54 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 7 news articles for Summit Therapeutics this week, compared to 9 articles on an average week.Search Interest84 people have searched for SMMT on MarketBeat in the last 30 days. This is an increase of 236% compared to the previous 30 days.MarketBeat Follows9 people have added Summit Therapeutics to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Company Ownership3.3 / 5Insider TradingAcquiring Shares Insider Buying vs. Insider SellingIn the past three months, Summit Therapeutics insiders have bought more of their company's stock than they have sold. Specifically, they have bought $11,969,512.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders84.90% of the stock of Summit Therapeutics is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by InstitutionsOnly 4.61% of the stock of Summit Therapeutics is held by institutions.Read more about Summit Therapeutics' insider trading history. Receive SMMT Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Summit Therapeutics and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsBy entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. SMMT Stock News HeadlinesSummit Therapeutics (NASDAQ:SMMT) CEO Robert Duggan Purchases 5,000 SharesSeptember 12, 2025 | insidertrades.comAnalysts Offer Insights on Healthcare Companies: Rocket Pharmaceuticals (RCKT), Summit Therapeutics (SMMT) and United Therapeutics (UTHR)October 5 at 10:44 AM | theglobeandmail.comURGENT: The Market's 3 Red Flags Are FlashingThe warning signs that preceded the 2008 crash are reappearing: an irrational NASDAQ bubble, a record-high gold price (signaling fear), and escalating geopolitical risk. A sharp correction might happen tomorrow, and most investors will be caught off guard. Your portfolio is currently exposed.October 5 at 2:00 AM | StockEarnings (Ad)1 Monster Stock in the Making to Buy and HoldOctober 5 at 9:45 AM | fool.comINVESTOR ALERT: Pomerantz Law Firm Investigates Claims On Behalf of Investors of Summit Therapeutics Inc. - SMMTOctober 3 at 10:00 AM | prnewswire.comA Look at Summit Therapeutics (SMMT) Valuation Following Phase III Trial Setback and Legal InvestigationOctober 2 at 4:04 PM | finance.yahoo.comH.C. Wainwright Reaffirms Price Target for Summit Therapeutics (SMMT) After Ivonescimab MilestonesOctober 2 at 2:18 AM | msn.comSummit Therapeutics Inc. (SMMT) Highlights Ivonescimab Progress at WCLC 2025October 1, 2025 | msn.comSee More Headlines SMMT Stock Analysis - Frequently Asked Questions How have SMMT shares performed this year? Summit Therapeutics' stock was trading at $17.84 on January 1st, 2025. Since then, SMMT stock has increased by 20.1% and is now trading at $21.43. How were Summit Therapeutics' earnings last quarter? Summit Therapeutics PLC (NASDAQ:SMMT) announced its quarterly earnings results on Monday, August, 11th. The company reported ($0.76) earnings per share for the quarter, missing the consensus estimate of ($0.10) by $0.66. When did Summit Therapeutics IPO? Summit Therapeutics (SMMT) raised $40 million in an initial public offering on Thursday, March 5th 2015. The company issued 3,500,000 shares at $11.54 per share. JMP Securities and Oppenheimer & Co. served as the underwriters for the IPO and Needham was co-manager. How do I buy shares of Summit Therapeutics? Shares of SMMT stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Summit Therapeutics own? Based on aggregate information from My MarketBeat watchlists, some other companies that Summit Therapeutics investors own include Invesco QQQ (QQQ), NVIDIA (NVDA), Meta Platforms (META), Advanced Micro Devices (AMD), Broadcom (AVGO), Adobe (ADBE) and CrowdStrike (CRWD). Company Calendar Last Earnings8/11/2025Today10/05/2025Next Earnings (Estimated)10/29/2025Fiscal Year End12/31/2025Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry MED - DRUGS Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:SMMT CIK1599298 Webwww.summitplc.com Phone650-460-8308Fax44-12-3544-3999Employees110Year Founded2003Price Target and Rating Average Price Target for Summit Therapeutics$31.29 High Price Target$50.00 Low Price Target$12.00 Potential Upside/Downside+46.0%Consensus RatingHold Rating Score (0-4)2.44 Research Coverage18 Analysts Profitability EPS (Trailing Twelve Months)($1.01) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$221.32 million Net MarginsN/A Pretax MarginN/A Return on Equity-208.64% Return on Assets-181.28% Debt Debt-to-Equity RatioN/A Current Ratio5.13 Quick Ratio5.13 Sales & Book Value Annual Sales$700 thousand Price / Sales22,741.82 Cash FlowN/A Price / Cash FlowN/A Book Value$0.53 per share Price / Book40.43Miscellaneous Outstanding Shares742,850,000Free Float112,170,000Market Cap$15.92 billion OptionableOptionable Beta-1.13 Social Links Beginner's Guide To Retirement StocksEnter your email address and we'll send you MarketBeat's list of seven best retirement stocks and why they should be in your portfolio. Get This Free Report This page (NASDAQ:SMMT) was last updated on 10/5/2025 by MarketBeat.com Staff From Our PartnersMagnificent 7 being replaced by the “Hidden 7”?BULLISH: It's time to buy this 'hidden' AI stock An award-winning stock-rating system has turned BULLISH on...Chaikin Analytics | SponsoredU.S. Government Sparking Crypto RallyU.S. Puts GDP on the Blockchain Could this spark the next crypto supercycle? Discover the altcoins poised t...Crypto 101 Media | SponsoredREVEALED: Something Big Happening Behind White House DoorsWhat I just learned about what’s unfolding in the White House is truly stunning… And you need to see it for...Paradigm Press | SponsoredURGENT: The Market's 3 Red Flags Are FlashingHere’s the uncomfortable truth: The smartest investors in the world are already preparing for a crash befor...StockEarnings | SponsoredForget Tesla — This Tiny AI Stock Is Musk’s Real PlayWhile Wall Street focused on Tesla’s earnings, Elon Musk was quietly building a supercomputer so powerful it c...Behind the Markets | SponsoredMelt-up warning Porter Stansberry says this bull market is past the “safe zone” and racing toward an event horizon — and in hi...Porter & Company | Sponsored2013 miner reveals his trading systemWhile everyone else is gambling on meme coins or chasing the next "100x moonshot," our members are systematica...Crypto Swap Profits | SponsoredRIP USA"The America you knew is dying in front of you" That's the urgent warning the former $200 million hedge fun...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Summit Therapeutics PLC Please log in to your account or sign up in order to add this asset to your watchlist. Share Summit Therapeutics With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.